Dr. Marion Mahnke
Angestellt, Principal Scientist, Novo Nordisk A/S
Måløv, Dänemark
Werdegang
Berufserfahrung von Marion Mahnke
Bis heute 5 Jahre und 10 Monate, seit Sep. 2018
Principal Scientist
Novo Nordisk A/S
Transfer of E.coli platform from China to Denmark. Successful project phase transitions and DRF batch completion within 5 month after transfer. Optimization projects in Yeast and E.coli for efficient incorporation of non-canonical (or unnatural) amino acids (ncAA or uAA) into therapeutic proteins during fed-batch and continuous cultivations.
2 Jahre und 5 Monate, Apr. 2016 - Aug. 2018
Department Manager
Novo Nordisk Research Center China
Leading a department focusing on therapeutic protein and peptide expression and purification as an integrated part of the global Novo Nordisk R&D organization. The department is responsible for early process development using Design of Experiment (DOE), documentation and process transfer to CMC in China and Denmark and protein production in mid to large scale in E.coli. Implementation of Process Analytical Technologies (PAT) and basic QbD principles in China.
9 Jahre und 9 Monate, Mai 2006 - Jan. 2016
Senior Research Investigator
Novartis Institutes for BioMedical Research
Technical project leadership for two single domain antibody projects until transfer to Preclinical Development Half life extension and delivery technology projects for antibody fragments and therapeutic proteins Strain engineering in E.coli and yeast (gene knock outs leading to improved protein quality and proprietary yeast display strain for generation of improved antibodies) Development of efficient processes and production of antigens, antibodies and therapeutic proteins.
3 Jahre, Jan. 2012 - Dez. 2014
Group Leader
Novartis Institutes for BioMedical Research
Leading a group of scientists in the field of Protein Expression and Purification using mainly Microbial Systems (such as E.coli, Pichia pastoris and baculo virus), purification and refolding techniques in order to produce therapeutic proteins and antigens. Global Strategy Team member for Microbial projects from Research to Clinical Production.
4 Jahre und 4 Monate, Jan. 2002 - Apr. 2006
Project Manager
Novartis Institutes for BioMedical Research
Innovation project team leader of an inter-disciplinary expression automation project comprising three expression systems: E.coli (automated multiparallel fermentation system), Baculo (wave system with automated harvest and online two step purification) and early development of a transient HEK system. Business plan, implementation and building a Protein Production Center at NIBR
5 Jahre, Jan. 1997 - Dez. 2001
Labhead
Novartis Pharma AG
Production of natural products and recombinant proteins Process development for production of immunotoxins in E.coli and Pichia pastoris
2 Jahre und 1 Monat, Dez. 1994 - Dez. 1996
Labhead
Sandoz
Process development for production of various Natural Products, such as FK506, Epothilon A, Sangliferin A using fungi, Actinomyces and Myxobacteria
2 Jahre und 5 Monate, Juli 1992 - Nov. 1994
Labhead
Ciba
Genetic and biochemical characterization of protein toxins from new isolates of Bacillus thuringiensis (or Bt), a Gram-positive, soil-dwelling bacterium, commonly used as a biological pesticide.
2 Jahre und 5 Monate, Feb. 1990 - Juni 1992
Postdoctoral Research Fellow
Ciba
Process Development for the production of Soraphen A using the Myxobacterium Sorangium cellulosum. Soraphen A was a highly effective agent against plant-pathogenic fungi. It was extensively researched for agricultural use until it was discovered to be a teratogen
Ausbildung von Marion Mahnke
1982 - 1989
Biologie
Eberhard-Karls-Universität Tübingen
Mikrobiologie, Biotechnologie, organische Chemie und Molekulargenetik
Sprachen
Deutsch
Muttersprache
Englisch
Fließend
Portugiesisch
Gut
Chinesisch
Grundlagen